ClinicalTrials.gg
CompletedNCT01451164Updated Oct 3, 2019Results posted

A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia

A Phase 2/3 interventional study of OPC-34712 and OPC-34712 in Schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-10-03.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
459
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
6th of 28
459 · median 155
Started
2011
with 6 others
Phase 2/3
Only one
of the 28
Registered
9th of 28
by date
Lead sponsor
2 of 28
Otsuka Pharmaceutical Co., Ltd.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 6th largest by enrollment, is one of 7 that started in 2011, is the only one in phase 2/3, and was the 9th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients age 18 years or older to less than 65 years (at time of ) diagnosed with schizophrenia based on diagnostic criteria
  • Patients who are hospitalized, or judged to required hospitalization, for acute relapse of schizophrenia at time of informed consent
  • Patients who are experiencing acute exacerbation of psychotic symptoms

Exclusion criteria

Exclusion Criteria:

  • Female patients who are breastfeeding or who have a positive pregnancy test (urine) result prior to receiving medicinal product
  • Patients presenting a first episode of schizophrenia based on the clinical judgment of the investigator
  • Patients who are diagnosed with a disease other than schizophrenia (schizoaffective disorder, major depressive disorder, bipolar disorder, posttraumatic stress disorder, anxiety disorder, delirium, dementia, amnesia, or other cognitive disorder) based on current Axis Ι criteria, or who are diagnosed with a personality disorder (borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
459 participants (actual)

Study arms

  • Experimental
    High dose

    Drug: OPC-34712

  • Experimental
    Mid dose

    Drug: OPC-34712

  • Experimental
    Low dose

    Drug: OPC-34712

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • orally administered once daily

  • orally administered once daily

  • orally administered once daily

  • DrugPlacebo

    orally administered once daily

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

Secondary outcomes

  1. Mean Change From Baseline to Week 6 in PANSS Positive Subscale Score.

    PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

  2. Mean Change From Baseline to Week 6 in PANSS Negative Subscale Score.

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

  3. Mean Change From Baseline to Week 6 in Clinical Global Impression-Severity of Illness (CGI-S)

    Severity of illness for each participant was rated using the CGI-S, which was the secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

  4. Mean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.

    The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

07

Results

Posted Oct 3, 2019

Participant flow

Participant flow — Overall Study
MilestoneBrexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlacebo
Started115115113116
Completed72816870
Not completed43344546
Withdrew: Adverse event19121821
Withdrew: Withdrawal criteria1111
Withdrew: Physician decision2010
Withdrew: Withdrawal by subject14111617
Withdrew: Protocol violation0100
Withdrew: Lack of efficacy7997

Outcome measures

PrimaryMean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleBrexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlacebo
Week1-2.68 ± 1.04-4.59 ± 1.03-3.42 ± 1.05-3.09 ± 1.03
Week2-5.07 ± 1.36-7.93 ± 1.33-6.80 ± 1.36-4.54 ± 1.34
Week3-6.92 ± 1.60-11.00 ± 1.55-9.42 ± 1.59-6.00 ± 1.58
Week4-8.40 ± 1.81-12.35 ± 1.74-11.21 ± 1.80-5.67 ± 1.80
Week5-8.13 ± 2.02-13.97 ± 1.93-11.09 ± 2.01-6.62 ± 2.03
Week6-8.26 ± 2.10-14.95 ± 2.00-11.49 ± 2.10-7.63 ± 2.11
SecondaryMean Change From Baseline to Week 6 in PANSS Positive Subscale Score.

PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 6 in PANSS Positive Subscale Score.
units on a scaleBrexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlacebo
Week1-0.96 ± 0.36-1.31 ± 0.36-0.70 ± 0.36-1.09 ± 0.35
Week2-1.72 ± 0.45-2.31 ± 0.44-1.61 ± 0.45-2.25 ± 0.44
Week3-2.07 ± 0.52-3.21 ± 0.51-2.71 ± 0.52-2.57 ± 0.52
Week4-2.39 ± 0.57-3.69 ± 0.54-3.09 ± 0.56-2.90 ± 0.56
Week5-2.19 ± 0.62-4.05 ± 0.60-2.89 ± 0.62-3.26 ± 0.63
Week6-2.22 ± 0.64-4.32 ± 0.61-3.15 ± 0.64-3.69 ± 0.64
SecondaryMean Change From Baseline to Week 6 in PANSS Negative Subscale Score.

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 6 in PANSS Negative Subscale Score.
units on a scaleBrexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlacebo
Week1-0.54 ± 0.27-0.83 ± 0.27-0.71 ± 0.27-0.59 ± 0.27
Week2-1.08 ± 0.37-1.46 ± 0.36-1.76 ± 0.36-0.72 ± 0.36
Week3-1.64 ± 0.41-2.41 ± 0.39-2.27 ± 0.40-1.14 ± 0.40
Week4-2.36 ± 0.46-2.90 ± 0.44-2.94 ± 0.46-0.81 ± 0.46
Week5-2.31 ± 0.52-3.24 ± 0.50-3.19 ± 0.52-0.85 ± 0.52
Week6-2.34 ± 0.55-3.48 ± 0.52-3.24 ± 0.55-1.20 ± 0.55
SecondaryMean Change From Baseline to Week 6 in Clinical Global Impression-Severity of Illness (CGI-S)

Severity of illness for each participant was rated using the CGI-S, which was the secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 6 in Clinical Global Impression-Severity of Illness (CGI-S)
units on a scaleBrexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlacebo
Week1-0.13 ± 0.06-0.18 ± 0.06-0.09 ± 0.06-0.15 ± 0.06
Week2-0.26 ± 0.08-0.36 ± 0.08-0.34 ± 0.08-0.25 ± 0.08
Week3-0.38 ± 0.09-0.52 ± 0.09-0.50 ± 0.09-0.36 ± 0.09
Week4-0.48 ± 0.09-0.62 ± 0.09-0.50 ± 0.09-0.40 ± 0.09
Week5-0.45 ± 0.11-0.81 ± 0.10-0.56 ± 0.10-0.52 ± 0.11
Week6-0.52 ± 0.11-0.85 ± 0.11-0.62 ± 0.11-0.57 ± 0.11
SecondaryMean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.

The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Mean · units on a scale
Mean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.
units on a scaleBrexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlacebo
Week13.87 ± 0.923.84 ± 0.964.01 ± 0.933.92 ± 1.04
Week23.87 ± 1.103.68 ± 1.023.79 ± 1.133.88 ± 1.26
Week33.89 ± 1.203.53 ± 1.043.77 ± 1.203.92 ± 1.36
Week43.83 ± 1.233.51 ± 1.163.81 ± 1.233.90 ± 1.36
Week53.92 ± 1.273.42 ± 1.233.76 ± 1.303.86 ± 1.48
Week63.90 ± 1.323.49 ± 1.303.78 ± 1.333.83 ± 1.49

Adverse events

Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 30 days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole 1mg0/115 (0%)8/115 (7%)49/115 (42.6%)
Brexpiprazole 2mg0/114 (0%)5/114 (4.4%)46/114 (40.4%)
Brexpiprazole 4mg0/113 (0%)5/113 (4.4%)49/113 (43.4%)
Placebo0/116 (0%)5/116 (4.3%)56/116 (48.3%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlacebo
SchizophreniaPsychiatric disorders7/1155/1144/1135/116
AsphyxiaRespiratory, thoracic and mediastinal disorders0/1150/1141/1130/116
Gastric ulcer haemorrhageGastrointestinal disorders0/1151/1140/1130/116
EosinophiliaBlood and lymphatic system disorders1/1150/1140/1130/116
Blood creatine phosphokinase increasedInvestigations1/1150/1140/1130/116
Electroencephalogram abnormalInvestigations1/1150/1140/1130/116
Psychiatric symptomPsychiatric disorders1/1150/1140/1130/116
Most frequent other events
Most frequent other events
EventBrexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlacebo
SchizophreniaPsychiatric disorders20/11513/11423/11328/116
NasopharyngitisInfections and infestations12/1158/11410/11311/116
HeadacheNervous system disorders8/1159/1143/1135/116
ConstipationGastrointestinal disorders8/1158/1147/1139/116
VomitingGastrointestinal disorders7/1155/1148/1134/116
AkathisiaNervous system disorders2/1154/1146/1138/116
Blood prolactin increasedInvestigations1/1153/1147/1133/116
DiarrhoeaGastrointestinal disorders4/1153/1146/1132/116
NauseaGastrointestinal disorders4/1156/1143/1132/116
Dental cariesGastrointestinal disorders6/1150/1144/1131/116

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Brexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlaceboTotal
<=18 years00000
Between 18 and 65 years115115113116459
>=65 years00000
Age, Continuous
Age, Continuous(years)Brexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlaceboTotal
Mean44.7 ± 11.543.3 ± 12.044.1 ± 11.945.0 ± 11.944.3 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlaceboTotal
Female64545865241
Male51615551218
Region of Enrollment
Region of Enrollment(participants)Brexpiprazole 1mgBrexpiprazole 2mgBrexpiprazole 4mgPlaceboTotal
Japan115115113116459
08

Study locations

1 site
  • Kanto Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011 and a primary completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2011
First posted
Oct 13, 2011
Start
Oct 2011
Primary completionActual
Jun 2015
Results first posted
Oct 3, 2019
Last update
Oct 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01451164
Responsible party
Sponsor
First posted
Oct 13, 2011
Start date
Oct 2011
Primary completion
Jun 2015
Results posted
Oct 3, 2019
Last update
Oct 3, 2019

Study contacts

kyoji Imaoka, Operating Officer
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion